TGEN starts Phase II trial

Targeted Genetics (TGEN) began a U.S. Phase II trial of its tgDCC-E1A non-viral DC-cholesterol delivery of the E1A tumor suppressor gene in combination with radiation therapy in up to 50 patients with...